Cargando…

Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study

OBJECTIVES: To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM). DESIGN: Prospective birth cohort study. SETTING: Bradford, UK. PARTICIPANTS: 762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton...

Descripción completa

Detalles Bibliográficos
Autores principales: Martine-Edith, Gilberte, Johnson, William, Hunsicker, Eugenie, Hamer, Mark, Petherick, Emily S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572403/
https://www.ncbi.nlm.nih.gov/pubmed/34732497
http://dx.doi.org/10.1136/bmjopen-2021-053753
_version_ 1784595208184266752
author Martine-Edith, Gilberte
Johnson, William
Hunsicker, Eugenie
Hamer, Mark
Petherick, Emily S
author_facet Martine-Edith, Gilberte
Johnson, William
Hunsicker, Eugenie
Hamer, Mark
Petherick, Emily S
author_sort Martine-Edith, Gilberte
collection PubMed
description OBJECTIVES: To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM). DESIGN: Prospective birth cohort study. SETTING: Bradford, UK. PARTICIPANTS: 762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton pregnancy. BiB cohort participants were recruited from 2007 to 2010. All women booked for delivery were screened for GDM between 26 and 28 weeks of gestation using a 75 g 2-hour oral glucose tolerance test (OGTT). OUTCOME MEASURE: GDM treatment type: lifestyle changes advice (lifestyle changes), lifestyle changes advice with supplementary insulin (insulin) and lifestyle changes advice with supplementary metformin (metformin). RESULTS: 244 (32%) women were prescribed lifestyle changes advice alone while 518 (68%) were offered supplemental pharmaceutical treatment. The odds of receiving pharmaceutical treatment relative to lifestyle changes advice alone were increased for mothers who were obese (OR 4.6, 95% CI 2.8 to 7.5), those who smoked (OR 2.6, 95% CI 1.2 to 5.5) and had higher fasting glucose levels at OGTT (OR 2.1, 95% CI 1.6 to 2.7). The odds of being prescribed pharmaceutical treatment rather than lifestyle changes advice were lower for Pakistani women (OR 0.7, 95% CI 0.4 to 1.0)) than White British women. Relative to insulin treatment, metformin was more likely to be offered to obese women than normal weight women (relative risk ratio, RRR 3.2, 95% CI 1.3 to 7.8) and less likely to be prescribed to women with higher fasting glucose concentrations at OGTT (RRR 0.3, 95% CI 0.2 to 0.6). CONCLUSIONS: In the BiB cohort, GDM pharmaceutical treatment tended to be prescribed to women who were obese, White British, who smoked and had more severe hyperglycaemia. The characteristics of metformin-treated mothers differed from those of insulin-treated mothers as they were more likely to be obese but had lower glucose concentrations at diagnosis.
format Online
Article
Text
id pubmed-8572403
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-85724032021-11-17 Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study Martine-Edith, Gilberte Johnson, William Hunsicker, Eugenie Hamer, Mark Petherick, Emily S BMJ Open Epidemiology OBJECTIVES: To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM). DESIGN: Prospective birth cohort study. SETTING: Bradford, UK. PARTICIPANTS: 762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton pregnancy. BiB cohort participants were recruited from 2007 to 2010. All women booked for delivery were screened for GDM between 26 and 28 weeks of gestation using a 75 g 2-hour oral glucose tolerance test (OGTT). OUTCOME MEASURE: GDM treatment type: lifestyle changes advice (lifestyle changes), lifestyle changes advice with supplementary insulin (insulin) and lifestyle changes advice with supplementary metformin (metformin). RESULTS: 244 (32%) women were prescribed lifestyle changes advice alone while 518 (68%) were offered supplemental pharmaceutical treatment. The odds of receiving pharmaceutical treatment relative to lifestyle changes advice alone were increased for mothers who were obese (OR 4.6, 95% CI 2.8 to 7.5), those who smoked (OR 2.6, 95% CI 1.2 to 5.5) and had higher fasting glucose levels at OGTT (OR 2.1, 95% CI 1.6 to 2.7). The odds of being prescribed pharmaceutical treatment rather than lifestyle changes advice were lower for Pakistani women (OR 0.7, 95% CI 0.4 to 1.0)) than White British women. Relative to insulin treatment, metformin was more likely to be offered to obese women than normal weight women (relative risk ratio, RRR 3.2, 95% CI 1.3 to 7.8) and less likely to be prescribed to women with higher fasting glucose concentrations at OGTT (RRR 0.3, 95% CI 0.2 to 0.6). CONCLUSIONS: In the BiB cohort, GDM pharmaceutical treatment tended to be prescribed to women who were obese, White British, who smoked and had more severe hyperglycaemia. The characteristics of metformin-treated mothers differed from those of insulin-treated mothers as they were more likely to be obese but had lower glucose concentrations at diagnosis. BMJ Publishing Group 2021-11-03 /pmc/articles/PMC8572403/ /pubmed/34732497 http://dx.doi.org/10.1136/bmjopen-2021-053753 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Martine-Edith, Gilberte
Johnson, William
Hunsicker, Eugenie
Hamer, Mark
Petherick, Emily S
Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title_full Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title_fullStr Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title_full_unstemmed Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title_short Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study
title_sort associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the uk born in bradford (bib) cohort study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572403/
https://www.ncbi.nlm.nih.gov/pubmed/34732497
http://dx.doi.org/10.1136/bmjopen-2021-053753
work_keys_str_mv AT martineedithgilberte associationsbetweenmaternalcharacteristicsandpharmaceuticaltreatmentofgestationaldiabetesananalysisoftheukborninbradfordbibcohortstudy
AT johnsonwilliam associationsbetweenmaternalcharacteristicsandpharmaceuticaltreatmentofgestationaldiabetesananalysisoftheukborninbradfordbibcohortstudy
AT hunsickereugenie associationsbetweenmaternalcharacteristicsandpharmaceuticaltreatmentofgestationaldiabetesananalysisoftheukborninbradfordbibcohortstudy
AT hamermark associationsbetweenmaternalcharacteristicsandpharmaceuticaltreatmentofgestationaldiabetesananalysisoftheukborninbradfordbibcohortstudy
AT petherickemilys associationsbetweenmaternalcharacteristicsandpharmaceuticaltreatmentofgestationaldiabetesananalysisoftheukborninbradfordbibcohortstudy